Exascale Labs Holdings Inc. (XLAB) Key Metrics
XLAB valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $151.2M
- Enterprise value
- $172.8M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 10.2
- Price / book
- —
- EV / EBITDA
- —
- Dividend yield
- —
- Beta
- —
XLAB key metrics, FY2024–FY2025
Fiscal year ended June 30, 2025 · U.S. dollarsXLAB returns How much profit the business earns on the capital it uses.
Return on assets−17.9 pts
−130.8%
FY2025 · hover or tap a bar for each year
FY2024FY2025
Free cash flow margin+30.2 pts
−14.4%
FY2025 · hover or tap a bar for each year
FY2024FY2025
Asset turnover+298.8%
1.20
FY2025 · hover or tap a bar for each year
FY2024FY2025
XLAB per-share figures Results divided by the shares outstanding at year-end.
Revenue per share+431.8%
$0.11
FY2025 · hover or tap a bar for each year
FY2024FY2025
Earnings per share
−$0.12
FY2025 · hover or tap a bar for each year
FY2024FY2025
Free cash flow per share
−$0.02
FY2025 · hover or tap a bar for each year
FY2024FY2025
Book value per share
−$0.21
FY2025 · hover or tap a bar for each year
FY2024FY2025
Shares outstanding0.0%
63.2M
FY2025 · hover or tap a bar for each year
FY2024FY2025
XLAB financial health Debt, liquidity and how easily interest is covered.
Net debt−$3.3M
−$4.2M
FY2025 · hover or tap a bar for each year
FY2024FY2025
Current ratio−18.7%
0.36
FY2025 · hover or tap a bar for each year
FY2024FY2025
XLAB efficiency & capital use Working capital cycle and where the cash goes.
Days sales outstanding−27 days
7 days
FY2025 · hover or tap a bar for each year
FY2024FY2025
Days payables outstanding−30 days
7 days
FY2025 · hover or tap a bar for each year
FY2024FY2025
Cash conversion cycle+3 days
0 days
FY2025 · hover or tap a bar for each year
FY2024FY2025
Capex / revenue−2.1 pts
0.0%
FY2025 · hover or tap a bar for each year
FY2024FY2025
XLAB returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
XLAB debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
XLAB key metrics
FY2024–FY2025| FY2025 | FY2024 | |
|---|---|---|
| Per share | ||
| Revenue per share | $0.11 | $0.02 |
| Earnings per share | −$0.12 | −$0.08 |
| Operating cash flow per share | −$0.02 | −$0.01 |
| Free cash flow per share | −$0.02 | −$0.01 |
| Cash per share | $0.07 | $0.02 |
| Book value per share | −$0.21 | −$0.09 |
| Tangible book value per share | −$0.21 | −$0.09 |
| Capex per share | $0.00 | $0.00 |
| Shares outstanding | 63.2M | 63.2M |
| Change in shares outstanding | 0.0% | — |
| Returns & profitability | ||
| Return on assets (ROA) | −130.8% | −112.9% |
| Return on tangible assets | −104.6% | −112.9% |
| Free cash flow margin | −14.4% | −44.6% |
| Financial health | ||
| Cash & short-term investments | $4.2M | $969,626 |
| Net debt | −$4.2M | −$969,626 |
| Current ratio | 0.36 | 0.44 |
| Quick ratio | 0.36 | 0.44 |
| Working capital | −$13.0M | −$5.5M |
| Invested capital | −$17.2M | −$6.5M |
| Tangible asset value | −$13.0M | −$5.5M |
| Net current asset value | −$13.0M | −$5.5M |
| Graham net-net per share | −$0.25 | −$0.14 |
| Capital allocation | ||
| Capex / revenue | 0.0% | 2.1% |
| Capex / depreciation | 0.34 | 6.77 |
| Stock-based compensation / revenue | 2.2% | 1.6% |
| R&D / revenue | 39.9% | 103.5% |
| SG&A / revenue | 19.3% | 40.6% |
| Efficiency | ||
| Days sales outstanding | 7.2 | 34.1 |
| Days payables outstanding | 6.7 | 37.0 |
| Cash conversion cycle (days) | 0.4 | -2.9 |
| Receivables turnover | 50.86 | 10.70 |
| Payables turnover | 54.21 | 9.87 |
| Asset turnover | 1.20 | 0.30 |
| Average receivables | $137,934 | $123,332 |
| Average payables | $109,028 | $128,040 |
| Intangibles / total assets | 0.0% | 0.0% |
Computed from XLAB's annual financial statements (latest annual report filed —) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
XLAB valuation and financial ratios
See the XLAB income statement, the XLAB chart for price history, or the XLAB stock overview for the latest quote and news.
XLAB key metrics FAQ
What is Exascale Labs's current ratio?
Exascale Labs's current ratio was 0.36 at the end of fiscal 2025: current assets were 0.36 times current liabilities.